Actas Urol Esp (Engl Ed)
- FERNANDEZ MI
Implementation of new treatments for BCG-unresponsive non-muscle-invasive bladder
cancer. Considerations in Latin America.
Actas Urol Esp (Engl Ed). 2024 Apr 12:S2173-5786(24)00058.
Biochem Genet
- XIE T, Guo J, Wang W
The Long Noncoding RNA Gall Bladder Cancer-Associated Suppressor of Pyruvate
Carboxylase Inhibits the Proliferation, Migration, and Invasion of Colorectal
Cancer Cells and Induces Their Apoptosis.
Biochem Genet. 2024 Apr 12. doi: 10.1007/s10528-024-10786.
Biol Direct
- SHEN D, Kang S
Correction: Comprehensive analysis of mitochondria-related genes indicates that
PPP2R2B is a novel biomarker and promotes the progression of bladder cancer via
Wnt signaling pathway.
Biol Direct. 2024;19:27.
BJU Int
- LAUKHTINA E, Gontero P, Babjuk M, Moschini M, et al
Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder
cancer.
BJU Int. 2024 Apr 16. doi: 10.1111/bju.16371.
- DITONNO F, Veccia A, Montanaro F, Pettenuzzo G, et al
Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder
cancer: a systematic review and meta-analysis of comparative studies.
BJU Int. 2024 Apr 15. doi: 10.1111/bju.16366.
- LONGONI M, Scilipoti P, Re C, Rosiello G, et al
Use of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) PET/CT for lymph node assessment
before radical cystectomy in bladder cancer patients.
BJU Int. 2024 Apr 15. doi: 10.1111/bju.16363.
- VAN KESSEL CS, Palma CA, Solomon MJ, Leslie S, et al
Comparison of urological outcomes and quality of life after pelvic exenteration:
partial vs radical cystectomy.
BJU Int. 2024;133 Suppl 4:53-63.
- BOTROS A, Rival PM, Page F, Davis ID, et al
Quality of transurethral resection of bladder tumour documentation: implications
for non-muscle-invasive bladder cancer risk stratification and management.
BJU Int. 2024;133 Suppl 4:7-10.
BJUI Compass
- AL-ZUBAIDI M, Ong K, Viswambaram P, Bangash H, et al
Comparing fluorodeoxyglucose positron emission tomography with computed
tomography in staging for nodal and distant metastasis in urothelial/bladder
cancer.
BJUI Compass. 2024;5:473-479.
BMC Urol
- YANG Y, Li J, Yao W, Zou G, et al
Diagnostic value of urine cyclic RNA-0071196 for bladder urothelial carcinoma.
BMC Urol. 2024;24:88.
Bratisl Lek Listy
- VARCHULOVA NOVAKOVA Z, Harsanyi S, Bevizova K, Kuniakova M, et al
Expression of BCL2, TP53, FOXA1, and GATA3 in pTa bladder cancer recurrence.
Bratisl Lek Listy. 2024;125:311-317.
Cancer Immunol Immunother
- MASSARI F, Santoni M, Takeshita H, Okada Y, et al
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma
after platinum-based chemotherapy: the ARON-2 study.
Cancer Immunol Immunother. 2024;73:106.
Cancers (Basel)
- YOO YC, Kim NY, Shin S, Yang Y, et al
Anti-Proliferative Effects of Lidocaine as an Autophagy Inducer in Bladder Cancer
via Intravesical Instillation: In Vitro and Xenograft Mouse Model Experiments.
Cancers (Basel). 2024;16:1267.
- AFONSO J, Barbosa-Matos C, Silvestre R, Pereira-Vieira J, et al
Cisplatin-Resistant Urothelial Bladder Cancer Cells Undergo Metabolic
Reprogramming beyond the Warburg Effect.
Cancers (Basel). 2024;16:1418.
- JAROMIN M, Konecki T, Kutwin P
Revolutionizing Treatment: Breakthrough Approaches for BCG-Unresponsive
Non-Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2024;16:1366.
- MAAS M, Hilsendecker A, Pertoll A, Stuhler V, et al
PD-L1 Expression in High-Risk Non-Muscle-Invasive Bladder Cancer Is Influenced by
Intravesical Bacillus Calmette-Guerin (BCG) Therapy.
Cancers (Basel). 2024;16:1356.
- PERRI D, Rocco B, Sighinolfi MC, Bove P, et al
Open versus Robot-Assisted Radical Cystectomy for the Treatment of pT4a Bladder
Cancer: Comparison of Perioperative Outcomes.
Cancers (Basel). 2024;16:1329.
- LADI-SEYEDIAN SS, Ghoreifi A, Konety B, Pohar K, et al
Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light
Cystoscopy: Insights from a Multicenter Registry.
Cancers (Basel). 2024;16:1268.
Cell Genom
- NAKAUMA-GONZALEZ JA, Rijnders M, Noordsij MTW, Martens JWM, et al
Whole-genome mapping of APOBEC mutagenesis in metastatic urothelial carcinoma
identifies driver hotspot mutations and a novel mutational signature.
Cell Genom. 2024;4:100528.
Clin Genitourin Cancer
- KLEMM J, Shariat SF, Laukhtina E, Rajwa P, et al
Impact of Preoperative Plasma Potassium Levels on Oncological Outcomes, Major
Complications, and 30-Day Mortality in Bladder Cancer Patients Undergoing Radical
Cystectomy.
Clin Genitourin Cancer. 2024 Mar 21:102079. doi: 10.1016/j.clgc.2024.102079.
- WANG A, Chen M, Li D, Shi J, et al
Disitamab Vedotin Alone or in Combination With Immune Checkpoint Inhibitors in
Bladder-Sparing Treatment of Muscle-Invasive Bladder Cancer: A Real-World Study.
Clin Genitourin Cancer. 2024;22:102085.
Curr Opin Urol
- ERTL I, Shariat SF, Berger W, Englinger B, et al
Preclinical models for bladder cancer therapy research.
Curr Opin Urol. 2024 Apr 17. doi: 10.1097/MOU.0000000000001182.
Egypt J Immunol
- ABD ELHAMEED ZA, Tag El Din LM, Sherif T, Abdel Aal AM, et al
Plasma metadherin mRNA expression in bladder cancer.
Egypt J Immunol. 2024;31:28-43.
Eur Urol
- ST-LAURENT MP, Black PC
Re: FGFR Inhibition Augments Anti-PD-1 Efficacy in Murine FGFR3-mutant Bladder
Cancer by Abrogating Immunosuppression.
Eur Urol. 2024 Apr 12:S0302-2838(24)02259-0. doi: 10.1016/j.eururo.2024.
- THALMANN GN
Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion Versus
Open Radical Surgery: All Is in the Eye of the Beholder.
Eur Urol. 2024;85:431-432.
- MASTROIANNI R, Tuderti G, Ferriero M, Anceschi U, et al
Robot-assisted Radical Cystectomy with Totally Intracorporeal Urinary Diversion
Versus Open Radical Cystectomy: 3-Year Outcomes from a Randomised Controlled
Trial.
Eur Urol. 2024;85:422-430.
Eur Urol Oncol
- RANA Z, Kamran SC, Shetty AC, Sutera P, et al
Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder
Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524
and RTOG 0712.
Eur Urol Oncol. 2024 Apr 18:S2588-9311(24)00095.
Front Immunol
- PEZESHKI A, Cheville JC, Florio AB, Leibovich BC, et al
Evaluation of tumor response to immune checkpoint inhibitors by a 3D
immunotumoroid model.
Front Immunol. 2024;15:1356144.
Georgian Med News
- VOVK V, Duda I, Vovk A
THE EFFECT OF A MULTIMODAL APPROACH ON THE RESULTS OF TREATMENT IN SURGERY:
INTEGRATION OF CHEMOTHERAPY, SURGERY, AND RADIOTHERAPY.
Georgian Med News. 2024;:41-46.
Int J Mol Sci
- PADULLES B, Carrasco R, Ingelmo-Torres M, Roldan FL, et al
Prognostic Value of Liquid-Biopsy-Based Biomarkers in Upper Tract Urothelial
Carcinoma.
Int J Mol Sci. 2024;25:3695.
- BAEK SW, Leem SH
A Multi-Gene Signature of Non-Muscle-Invasive Bladder Cancer Identifies Patients
Who Respond to Immunotherapies Including Bacillus Calmette-Guerin and Immune
Checkpoint Inhibitors.
Int J Mol Sci. 2024;25:3800.
Int J Urol
- URABE F
Letter to the Editor Re: Variant histology is associated with more non-urothelial
tract recurrence but less intravesical recurrence upper tract urothelial
carcinoma after radical nephroureterectomy.
Int J Urol. 2024;31:420.
- HIYAMA Y
Editorial comment to Lower bleeding volume contributes to decreasing surgical
site infection in radical cystectomy: A propensity score-matched comparison of
open versus robot-assisted radical cystectomy.
Int J Urol. 2024;31:437.
- TAOKA R, Sugimoto M
Editorial Comment on Variant histology is associated with more non-urothelial
tract recurrence but less intravesical recurrence for upper tract urothelial
carcinoma after radical nephroureterectomy.
Int J Urol. 2024;31:418-419.
- LUO HL
Variant histology is associated with more non-urothelial tract recurrence but
less intravesical recurrence upper tract urothelial carcinoma after radical
nephroureterectomy.
Int J Urol. 2024;31:421.
- HAYAKAWA N, Kikuchi E
Editorial comment to "The clinical impact of ureteroscopy for upper tract
urothelial carcinoma: A multicenter study".
Int J Urol. 2024;31:402-403.
- SAZUKA T
Editorial Comment on "The clinical impact of ureteroscopy for upper tract
urothelial carcinoma: A multicenter study".
Int J Urol. 2024;31:401-402.
- TAGUCHI S
Editorial comment from Dr Taguchi to Real world evidence of enfortumab vedotin in
patients with advanced urothelial cancer: A multicenter observational study.
Int J Urol. 2024;31:348.
- SOWANTHIP D, Zennami K, Bejrananda T, Nukaya T, et al
Older versus younger patients in robot-assisted radical cystectomy with
intracorporeal ileal conduit comparing safety and clinical outcomes.
Int J Urol. 2024;31:370-378.
- KAMEI J, Endo K, Yamazaki M, Sugihara T, et al
Lower bleeding volume contributes to decreasing surgical site infection in
radical cystectomy: A propensity score-matched comparison of open versus
robot-assisted radical cystectomy.
Int J Urol. 2024;31:430-437.
- SASAHARA T, Yanagisawa T, Sugaya S, Hisakane A, et al
Prognostic factors for overall survival in clinical node-positive patients with
upper tract urothelial carcinoma.
Int J Urol. 2024;31:386-393.
- YU TY, Wang HJ, Sung MT, Chuang YC, et al
Variant histology is associated with more non-urothelial tract recurrence but
less intravesical recurrence for upper tract urothelial carcinoma after radical
nephroureterectomy.
Int J Urol. 2024;31:410-418.
- NAKANO J, Urabe F, Kiuchi Y, Takamizawa S, et al
The clinical impact of ureteroscopy for upper tract urothelial carcinoma: A
multicenter study.
Int J Urol. 2024;31:394-401.
- URABE F, Ito K, Kimura T
Letter to the Editor Re: Balancing diagnostic advancements with cardiovascular
considerations in 5-aminolevulinic acid use for bladder tumors.
Int J Urol. 2024;31:452.
iScience
- CHEN H, Wen J, Zhang W, Ma W, et al
circKDM1A suppresses bladder cancer progression by sponging miR-889-3p/CPEB3 and
stabilizing p53 mRNA.
iScience. 2024;27:109624.
J Cancer Res Clin Oncol
- LI J, Song Y, Peng Y, Lin J, et al
The role of histological subtype and chemotherapy on prognosis of ureteral
cancer.
J Cancer Res Clin Oncol. 2024;150:192.
J Clin Med
- PICHLER R, Stablein J, Mari A, Afferi L, et al
Treating BCG-Induced Cystitis with Combined Chondroitin and Hyaluronic Acid
Instillations in Bladder Cancer.
J Clin Med. 2024;13:2031.
J Clin Oncol
- SHENG X, Wang L, He Z, Shi Y, et al
Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth
Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A
Combined Analysis of Two Phase II Clinical Trials.
J Clin Oncol. 2024;42:1391-1402.
J Clin Tuberc Other Mycobact Dis
- HARTERT M, Deppe C, Fink L, Kappes J, et al
Chest wall tumor following intravesical BCG instillation for non-muscle invasive
bladder cancer.
J Clin Tuberc Other Mycobact Dis. 2024;35:100438.
J Immunother Cancer
- MEGHANI K, Frydenlund N, Yu Y, Choy B, et al
Spatial comparison of molecular features associated with resistance to
pembrolizumab in BCG unresponsive bladder cancer.
J Immunother Cancer. 2024;12:e008571.
J Transl Med
- ZHENG K, Hai Y, Chen H, Zhang Y, et al
Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer:
a novel molecular subtyping strategy and immunotherapeutic prediction model.
J Transl Med. 2024;22:365.
JCO Precis Oncol
- GONG J, Mita AC, Wei Z, Cheng HH, et al
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth
Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial
(EAY131) Subprotocol K2.
JCO Precis Oncol. 2024;8:e2300407.
- GONG J, Mita AC, Wei Z, Cheng HH, et al
Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications:
Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1.
JCO Precis Oncol. 2024;8:e2300406.
Med Biol Eng Comput
- ZHAO X, Lai L, Li Y, Zhou X, et al
A lightweight bladder tumor segmentation method based on attention mechanism.
Med Biol Eng Comput. 2024;62:1519-1534.
Mol Carcinog
- QING L, Li Q, Yang Y, Xu W, et al
Hypoxia-mediated attenuation of EGLN2 inhibition of the NF-kappaB signaling pathway
leads to the formation of a loop between HIF-1alpha and MUC1-C promoting
chemoresistance in bladder cancer.
Mol Carcinog. 2024 Apr 18. doi: 10.1002/mc.23725.
Nat Rev Urol
- MASONE MC
A CAF subpopulation promotes LVI in early-stage bladder cancer.
Nat Rev Urol. 2024 Apr 15. doi: 10.1038/s41585-024-00881.
NPJ Digit Med
- KWONG JCC, Wu J, Malik S, Khondker A, et al
Predicting non-muscle invasive bladder cancer outcomes using artificial
intelligence: a systematic review using APPRAISE-AI.
NPJ Digit Med. 2024;7:98.
Urol Oncol
- HERZBERG H, Ventura Y, Lifshitz K, Savin Z, et al
Natural history and health care burden of non-curative treatment for
muscle-invasive bladder cancer.
Urol Oncol. 2024 Apr 18:S1078-1439(24)00365.
- FEBRIYANTO T, Muhammad F, Wijaya W, Oey O, et al
Antibiotic use reduces the efficacy of immune checkpoint inhibitors in patients
with urothelial carcinoma: A systematic review and meta-analysis.
Urol Oncol. 2024;42:160.
- GREENBERG DR, Rhodes S, Bhambhvani HP, Gago LC, et al
The association between frailty, hypogonadism, and postoperative outcomes among
men undergoing radical cystectomy.
Urol Oncol. 2024;42:161.
- MORRA S, Scheipner L, Baudo A, Jannello LMI, et al
Regional differences in upper tract urothelial carcinoma patients across the
United States.
Urol Oncol. 2024;42:162.
- DALL CP, Mason JB, Goldman CC, Fabrizio G, et al
Functional and oncologic outcomes of prostate capsule-sparing radical cystectomy:
A systematic review and meta-analysis.
Urol Oncol. 2024;42:121-132.
Urology
- SAHNI DS, Oberoi AS, Ramsaha S, Teahan S, et al
Incidence of Ureteroenteric Anastomotic Strictures After Robotic vs Open
Cystectomy in Adults.
Urology. 2024;185:100-108.
World J Urol
- WEBER A, Vignat J, Shah R, Morgan E, et al
Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN
estimates.
World J Urol. 2024;42:237.
Zhonghua Nan Ke Xue
- JIANG Q, Wei ZF, Xiong Y, Jiang B, et al
[Identification of lncrnas associated with aniline toxicity in male bladder
cancer and construction of tumor risk prediction models].
Zhonghua Nan Ke Xue. 2023;29:790-798.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016